SMC recommends Yselty for treating uterine fibroids

New treatment option approved for women in Scotland

The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for treating moderate to severe symptoms of uterine fibroids (UFs) in women of reproductive age.

This decision means eligible women across Scotland can now access this treatment through the NHS.

Uterine fibroids affect approximately 70% of women of reproductive age, with black women being two to three times more likely to develop these tumors compared to white women.

About 25% of women experience severe symptoms that require treatment, which can include pelvic pressure, back or abdominal pain, heavy bleeding, and other complications.

“The SMC’s approval of Yselty is a significant milestone for women’s health in Scotland. As both a GP and advocate for women’s healthcare, I am delighted to see more treatment options becoming available,” said Dr Sigi Joseph, Co-Founder of The Doctor Explains.

The approval is based on data from two PRIMROSE studies that investigated the efficacy and safety of Yselty® in women with uterine fibroids and heavy menstrual bleeding.

“The recommendation is a step towards closing the gender health gap and ensuring that women have access to a wider range of evidence-based treatments. Having more approved medications gives us greater flexibility in tailoring care to individual needs,” Dr Joseph added.

Tina Backhouse, UK General Manager at Theramex, emphasized the importance of this decision: “Women should not have to endure painful gynaecological conditions – and uterine fibroids are just one of many issues in women’s health that need immediate improvement. We are committed to working closely with SMC and NHS Scotland to ensure that eligible women in Scotland will now have access to Yselty – diversifying their treatment options.”

This recommendation marks a significant advancement in addressing the health needs of women, providing new hope for those affected by uterine fibroids.